Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA Study

Solbu, M. D., Mjøen, G., Mark, P. B. , Holdaas, H., Fellström, B., Schmieder, R. E., Zannad, F., Herrington, W. G. and Jardine, A. G. (2018) Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA Study. Nephrology Dialysis Transplantation, 33(1), pp. 102-112. (doi: 10.1093/ndt/gfw360) (PMID:27798199)

[img]
Preview
Text
128686.pdf - Accepted Version

763kB

Abstract

Background: Patients on haemodialysis (HD) are at high risk for cardiovascular events, but heart failure and sudden death are more common than atherosclerotic events. The A Study to Evaluate the Use of Rosuvastatinin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) trial was designed to assess the effect of rosuvastatin on myocardial infarction and death from any cardiac cause in 2773 HD patients. We studied predictors of the atherosclerotic cardiovascular events in AURORA. Methods: We readjudicated all deaths and presumed myocardial infarctions according to the criteria used in the Study of Heart and Renal Protection (SHARP); these were specifically developed to separate atherosclerotic from non-atherosclerotic cardiovascular events. The readjudicated atherosclerotic end point included the first event of the following: non-fatal myocardial infarction, fatal coronary heart disease, non-fatal and fatal non-haemorrhagic stroke, coronary revascularization procedures and death from ischaemic limb disease. Stepwise Cox regression analysis was used to identify the predictors of such events. Results: During a mean follow-up of 3.2 years, 506 patients experienced the new composite atherosclerotic outcome. Age, male sex, prevalent diabetes, prior cardiovascular disease, weekly dialysis duration, baseline albumin [hazard ratio (HR) 0.96; 95% confidence interval (CI) 0.94–0.99 per g/L increase], high-sensitivity C-reactive protein (HR 1.13; 95% CI 1.04–1.22 per mg/L increase) and oxidized low-density lipoprotein (LDL) cholesterol (HR 1.09; 95% CI 1.03–1.17 per 10 U/L increase) were selected as significant predictors in the model. Neither LDL cholesterol nor allocation to placebo/rosuvastatin therapy predicted the outcome. Conclusions: Even with the use of strict criteria for end point definition, non-traditional risk factors, but not lipid disturbances, predicted atherosclerotic events in HD patients.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mark, Dr Patrick and Solbu, Dr Marit Dahl and Jardine, Professor Alan
Authors: Solbu, M. D., Mjøen, G., Mark, P. B., Holdaas, H., Fellström, B., Schmieder, R. E., Zannad, F., Herrington, W. G., and Jardine, A. G.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Nephrology Dialysis Transplantation
Publisher:Oxford University Press
ISSN:0931-0509
ISSN (Online):1460-2385
Published Online:17 October 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Nephrology Dialysis Transplantation 33(1): 102-112
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record